Literature DB >> 9364925

Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme.

M Beaulieu1, E Lévesque, A Tchernof, B G Beatty, A Bélanger, D W Hum.   

Abstract

UGT2B17 is a UDP-glucuronosyltransferase enzyme expressed in several extrahepatic steroid target tissues, including the human prostate, where it glucuronidates C19 steroids such as dihydrotestosterone (DHT), androsterone (ADT), and androstane-3alpha, 17beta-diol (3alpha-diol). To determine if UGT2B17 is regulated by physiological effectors of the human prostate, DHT and epidermal growth factor (EGF) were demonstrated to specifically down-regulate the steady-state levels of UGT2B17 transcript and protein in LNCaP cells (Guillemette et al., 1997). These results implicate regulation of UGT2B17 at the level of gene transcription, therefore, a P-1-derived artificial chromosome (PAC) clone of 120 kb containing the entire UGT2B17 gene was isolated. The gene is comprised of six exons spanning approximately 30 kb, and fluorescence in situ hybridization of the UGT2B17 PAC clone to normal human lymphocyte chromosomes, mapped the gene to chromosome 4q13. To determine if the 5'-flanking DNA of the UGT2B17 gene is sufficient to confer gene expression, a 2,942-bp fragment was subcloned into a luciferase reporter plasmid and yielded an activity of 25-fold over background when transfected in LNCaP cells. However, transfection of the construct into HK-293, MCF-7, JEG-3, and HepG2 cells yielded only a moderate activity of two- to five-fold over background. Treatment of transfected LNCaP cells with 10 nM R1881, a nonmetabolizable analog of DHT, and 10 ng/ml EGF decreased the luciferase activity by 60%. This suggests that at least part, if not all, of the inhibitory effect of EGF and DHT on UGT2B17 is at the level of transcription. Progressive 5' deletions of the UGT2B17 5'-flanking region in the luciferase constructs alleviated the inhibition by R1881 and EGF, and revealed several potential responsive elements that may confer the observed regulation of the UGT2B17 gene. This study demonstrates regulation of the UGT2B17 gene by physiological effectors of the human prostate and supports the hypothesis that UGT enzymes are involved in steroid metabolism in extrahepatic tissues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364925     DOI: 10.1089/dna.1997.16.1143

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  18 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Frank Z Stanczyk; Kim C Westerlind; Katherine M Newton; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  J Steroid Biochem Mol Biol       Date:  2010-12-28       Impact factor: 4.292

3.  Cloning and characterization of a simian UDP-glucuronosyltransferase enzyme UGT2B20, a novel C19 steroid-conjugating protein.

Authors:  O Barbier; A Bélanger; D W Hum
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

4.  Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity.

Authors:  Carla J Gallagher; Renee M Balliet; Dongxiao Sun; Gang Chen; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2010-09-01       Impact factor: 3.922

5.  Germline copy number loss of UGT2B28 and gain of PLEC contribute to increased human esophageal squamous cell carcinoma risk in Southwest China.

Authors:  Liwen Hu; Yuanyuan Wu; Xingying Guan; Yan Liang; Xinyue Yao; Deli Tan; Yun Bai; Gang Xiong; Kang Yang
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

6.  Developmental aspects of human hepatic drug glucuronidation in young children and adults.

Authors:  C P Strassburg; A Strassburg; S Kneip; A Barut; R H Tukey; B Rodeck; M P Manns
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

7.  Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis.

Authors:  Ryan T Bushey; Gang Chen; Andrea S Blevins-Primeau; Jacek Krzeminski; Shantu Amin; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-02       Impact factor: 2.089

8.  UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility.

Authors:  Rene M Balliet; Gang Chen; Ryan W Dellinger; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2009-12-09       Impact factor: 3.922

9.  Isolation and characterization of the monkey UGT2B30 gene that encodes a uridine diphosphate-glucuronosyltransferase enzyme active on mineralocorticoid, glucocorticoid, androgen and oestrogen hormones.

Authors:  Caroline Girard; Olivier Barbier; David Turgeon; Alain Bélanger
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

10.  UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation.

Authors:  N Santos; R Rodríguez-Romanos; J B Nieto; I Buño; C Vallejo; A Jiménez-Velasco; S Brunet; E Buces; J López-Jiménez; M González; C Ferrá; A Sampol; R de la Cámara; C Martínez; D Gallardo
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.